The experience of colleagues physicians in application of phago-products will help to choose the optimal prevention and treatment regimen for a particular infectious disease
Treatment of cystitis with bacteriophages is advisable for both acute and chronic forms of the disease, especially when traditional uroantiseptics and antibiotics are ineffective. Common pathogens of infectious cystitis are destroyed by bacteriophages, wh
Representatives of opportunistic human flora often demonstrate multiple resistance to antibiotics. The use of bacteriophages in the treatment of purulent-inflammatory diseases of the ear, nose and throat allows not only to eliminate the infection, but als
When treating stomatitis, it is important to ensure disinfection of the oral cavity, eliminate pain and inflammation, and prevent the spread of infection. For the prevention and treatment of stomatitis, bacteriophage preparations are used, in particular t
Antibiotics for intestinal infections are prescribed only in the most severe cases. Most often, so-called intestinal antiseptics are used - drugs that act only in the intestinal lumen and are not always effective. An alternative to traditional antibacteri
For the prevention and treatment of purulent septic complications of wound processes, bacteriophages are used, in particular the drug Pyofag®. The drug has a bactericidal effect against a number of common pathogens, including antibiotic-resistant ones.
To eliminate opportunistic microflora, it is advisable to use appropriate bacteriophages. Phage preparations are highly specific - they destroy only certain bacteria without affecting beneficial microflora.
Register to receive additional information about phage therapy and phage preparations. Be sure to include your phone number so that we can contact you. Later, registered users will have access to the materials in the "For specialists" section, as well as an electronic newsletter and invitations to specialized events
Don't worry: Your personal data are safe
Phage therapy - is a field of medical microbiology, which is now actively developing and is the subject of numerous scientific and clinical studies, the "hot topic" of medical forums and congresses.
Scientists have developed the first fully synthetic method for building and reprogramming bacteriophages, offering a faster and safer route to designing virus-based treatments for drug-resistant bacteria.
The Phase 1b clinical trial of LBP-PA01 will enable Locus to evaluate safety, efficacy, and optimal dosing in patients with P. aeruginosa infections that are becoming increasingly difficult to treat with conventional antibiotics.
Since 2019, Belgium has approved the use of bacteriophages to treat antibiotic-resistant infections. More than 100 patients have already undergone treatment with bacterial viruses. The clinical case of one of them is described in the latest issue of the journal Nature Communications.
